AVROBIO Inc
NASDAQ:TECX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (19.1), the stock would be worth $-75.7 (365% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -7.2 | $28.54 |
0%
|
| Industry Average | 19.1 | $-75.7 |
-365%
|
| Country Average | 22.9 | $-90.49 |
-417%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
AVROBIO Inc
NASDAQ:TECX
|
534.8m USD | -7.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 30.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
AVROBIO Inc
Glance View
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of five lentiviral-based gene therapy programs, which include AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.
